ACET
Adicet Bio, Inc. [ACET] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ACET Stock Summary
Top ACET Correlated Resources
ACET
Top 10 Correlated ETFs
ACET
Top 10 Correlated Stocks
ACET
In the News
ACET Financial details
Company Rating
-
Market Cap
177.45M
Income
-141.4M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
143
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-1.06
Forward P/E
-
PEG
-0.1
P/S
-5.96
P/B
0.76
P/C
-
P/FCF
-1.49
Quick Ratio
9.27
Current Ratio
9.4
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.29
EPS next Y
-
EPS next Q
-
EPS this Y
103.07%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-24.11%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-40.52%
-
-
-
-
SMA20
14.29%
SMA50
14.29%
SMA100
-11.11%
Inst Own
-
Inst Trans
-
ROA
-60%
ROE
763%
ROC
-0.71%
Gross Margin
100%
Oper. Margin
608%
Profit Margin
560%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.1-7.5
52W High
+8%
52W Low
+656%
RSI
53
Rel Volume
0.06
Avg Volume
1.48M
Volume
91.99K
Perf Week
-6.2%
Perf Month
9.09%
Perf Quarter
-31.52%
Perf Half Y
-47.61%
-
-
-
-
Beta
1.624
-
-
Volatility
0.23%, 0.68%
Prev Close
-1.43%
Price
7.56
Change
-2.83%
Company Profile
- Volume Average 1.48M
- Market Capitalization 177.45M
- Employee 143
- CEO Mr. Chen Schor BA, CPA, M.B.A.
- Headquarters Boston,MA,US
- IPO Date 2018-01-26
-
Website
https://www.adicetbio.com 
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
